SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

DEGEN is a reward token for Farcaster users, born from meme culture. It features a unique tipping system that allows the community to reward high-quality content creators. DEGEN also powers the Degen Chain, one of the pioneering Layer 3s launched on Base. Known as the “Las Vegas of blockchains,” it provides a platform for building and using Degen apps, offering a space for fun, innovation, and community-driven experiences.

League of Degens 

DEGEN is capturing significant investor attention as the project transitions from a Farcaster tipping token into a brand-focused SocialFi ecosystem, driven by active token buyback and burn programs. Community discourse is currently polarized between optimistic long-term holders tracking upcoming app launches and skeptical traders debating the token's recent price volatility.

Vera Therapeutics, Inc. is a clinical stage biotechnical company which engages in the development and commercialization of transformative treatments for immunological diseases. The company was founded by Marshall Fordyce in May 2016 and is headquartered in Brisbane, CA.

Vera Therapeutics Inc - Ordinary Shares - Class A

Vera Therapeutics is trending as investors digest the recent public offering of Class A common stock alongside a robust clinical pipeline, which includes the upcoming BLA submission for its lead asset, atacicept. The community remains focused on the potential for a transformative commercial launch in the IgAN space, with frequent discussions centered on institutional confidence, acquisition speculation, and the company's competitive positioning relative to other B-cell modulators.

BRK690k is a memecoin experiment inspired by the legendary growth of Berkshire Hathaway Class A stock ($BRK.A), which rose from $250 to $690k over four decades. Created by the fictional character Barren Wuffett, the project embraces humor, creativity, and innovation through its Price-Patterned Tokenomics™, exploring whether a stock-to-meme narrative can achieve similar growth. BRK690k is both a satirical commentary on traditional finance and a community-driven effort to blend memecoins and stock-inspired value trajectories.

Breakout

The community is actively tracking technical breakouts across multiple sectors, with analysts highlighting strong volume support and consolidation patterns as indicators of potential momentum shifts. Discussions center on identifying high-probability setups and maintaining disciplined risk management amidst broader market volatility.

TRON is a decentralized blockchain-based operating system designed to accelerate the decentralization of the internet and its underlying infrastructure. It serves as a global settlement layer for stablecoins and everyday digital purchases, providing a high-throughput environment to support large-scale decentralized applications. The network is governed by a decentralized autonomous organization (DAO), which allows the community to manage the protocol without a central authority. Its primary value proposition includes a unique resource model that utilizes bandwidth and energy to allow for high transaction volumes without traditional fee spikes.  The platform functions as a smart contract platform that enables the creation of decentralized applications and is compatible with the Ethereum Virtual Machine, allowing developers to easily migrate applications. TRON operates using a Delegated Proof of Stake consensus mechanism where token holders vote for 27 Super Representatives to verify transactions and maintain the ledger. This structure is built for scalability and fast finality, aiming to handle more transactions per second than many established legacy blockchains. Users can interact with the ecosystem for various purposes, including decentralized finance (DeFi) through platforms like JustLend DAO and decentralized storage via the BitTorrent File System.  Value moves through the system via its native utility token, TRX, which facilitates transactions and grants users access to network resources. Holders can lock their TRX in a staking mechanism to gain TRON Power, which is used to vote on network rules and elect Super Representatives, earning rewards for securing the network. Established by the TRON Foundation and led by founder Justin Sun, the project has transitioned into a community-led DAO. The ecosystem is supported by strategic partnerships with major global entities, including Samsung, which integrated TRON into its blockchain keystore, as well as BitTorrent, Opera, and Swisscom Blockchain.

Tron

Tron is generating significant market interest due to its expanding utility in stablecoin settlements and high-profile ecosystem partnerships with companies like Tether and Rumble. Investors are actively discussing its resilient performance compared to other assets and speculating on potential long-term growth as the network integrates with major platforms like Coinbase's Base network.

Got that dog in you? - Fueled by a mantra of tokenized self-belief, doginme is representative of the community's collective efforts to embrace and embolden that dog in them. doginme stands for knowing yourself and having that unshakable drive to keep pushing forward. doginme was originally launched in February 2024 when the Farcaster founder was asked if he owned a dog, to which he replied affirmatively: "no but I got that dog in me"

doginme

DOGINME is generating significant community buzz as a Base-chain meme coin, with holders rallying around its "self-belief" narrative and cultural stickiness. Supporters are actively pointing to its low market cap and recent exchange listings as catalysts for future momentum, while discussions remain highly divided between those betting on an explosive run and skeptics dismissing the token as a scam.

Pi Network is a social cryptocurrency and developer platform designed to make digital currency mining accessible to everyday people through mobile devices. The project aims to build a widely distributed currency that facilitates transactions for real-world goods and services rather than purely speculative trading. Its main value proposition is a mobile-first mining system that allows users to earn rewards on their phones without requiring specialized hardware, draining battery life, or using excessive data.  The network operates on the Stellar Consensus Protocol and a Federated Byzantine Agreement, which allows computers to reach agreement by trusting specific groups of other peers. Security is maintained through a global trust graph built from individual user groups called security circles where members vouch for each other. Users participate in four primary roles as pioneers, contributors, ambassadors, or nodes to ensure the network remains decentralized. This meritocratic distribution model rewards consistent engagement and network growth rather than financial wealth or technical power.  Founded by Dr. Nicolas Kokkalis and Dr. Chengdiao Fan, both of whom hold doctoral degrees from Stanford University, the project is managed by Social Chain Inc. The ecosystem includes a native wallet, a dedicated browser, and a platform for decentralized applications where the PI token is used for peer-to-peer exchange and transaction fees. Additionally, tokens can be used for purchasing goods in an internal marketplace, staking in a launchpad, or voluntary lockups that support market stability while boosting personal mining rates. The project has focused on organic community growth and does not list any external institutional investors in its documentation.

Pi Network

Pi Network continues to draw intense debate as the community remains polarized between long-term believers citing the project's massive user base and ecosystem potential, and vocal critics who label it a scam due to limited liquidity and ongoing delays in releasing unverified balances. While sentiment is split, many users are actively monitoring for major exchange listings and mainnet migration progress as key indicators of the platform's future viability.

RoboStrategy, Inc. is a non-diversified, closed-end management investment company, which engages in investing in equity and equity-linked securities of private and public companies operating in the fields of robotics and embodied artificial intelligence. The company was founded on May 23, 2025 and is headquartered in San Juan, Puerto Rico.

RoboStrategy Inc

RoboStrategy, Inc.

RoboStrategy is trending as investors compare its early trading volatility to past IPO runs, with the community actively debating its exposure to private robotics firms like Figure AI. While some participants are wary of potential dilution and promotional activity, others are treating the stock as a speculative long-term play on the automation sector.

Virtuals Protocol is a launchpad platform launched in 2024 that enables users to create, tokenize, and monetize AI agents for gaming, entertainment, and virtual environments without requiring technical expertise. Initially built on Ethereum's Base Layer 2 network, the protocol has expanded to Ethereum mainnet, Solana, and Ronin as of 2025. VIRTUAL serves as the base liquidity pair and transactional currency for all AI agent interactions across the ecosystem.  The protocol operates through a bonding curve system where new AI agents are created with a 100 VIRTUAL fee. Users can buy and sell agent tokens until the agent reaches 42,000 VIRTUAL, at which point it graduates to a permanent liquidity pool paired with VIRTUAL. AI agents are multimodal, capable of text, speech, and 3D animation, and can manage on-chain wallets autonomously. Notable examples include Luna, an AI girl band vocalist with over 500,000 TikTok followers. The GAME framework powers agent functionality, enabling them to process inputs, generate responses, and remember past interactions.  Virtuals Protocol was founded by Jansen Teng and Weekee Tiew, evolving from PathDAO, a gaming guild established in 2021 that pivoted to AI agents in January 2024. The team raised $16 million in seed funding led by DeFiance Capital and Beam. In 2025, major partnerships were announced with Animoca Brands and a collaboration with Zyfai and BasisOS to launch an Agentic Fund of Funds.  Users can stake VIRTUAL tokens for veVIRTUAL to participate in DAO governance and may receive airdrops of agent tokens. When users interact with agents, they pay fees in VIRTUAL that generate protocol revenue. This revenue funds periodic buybacks and burns of the VIRTUAL token, reducing its total supply as a value-accrual mechanism for holders.

Virtual Protocol

Virtuals Protocol is seeing intense community discussion surrounding its potential in the burgeoning AI agent sector, with many participants citing its integration with major exchange listings and ecosystem growth as key drivers for long-term optimism. While some retail traders express frustration over recent price volatility, bulls remain focused on the project's utility as an orchestration layer for agentic AI and are actively watching for breakout signals toward higher price levels.

Rithm Capital Corp. engages in the provision of real estate, credit, and financial services. It operates through the following segments: Origination and Servicing, Investment Portfolio, Residential Transitional Lending, Asset Management, and Corporate. The Origination and Servicing segment includes residential mortgage loans underlying mortgage servicing right assets as well as those sub-service for third parties. The Investment Portfolio segment consists of residential mortgage loans, SFR properties, consumer loans, Non-Agency RMBS, Excess MSRs and servicer advance investments. The Residential Transitional Lending segment competes for both experienced sponsors, including developers and investors in residential real estate, and attractive lending opportunities based on several factors. The Asset Management segment focuses on the wholly owned subsidiaries, Sculptor, and RCM Manager. The company was founded on September 26, 2011 and is headquartered in New York, NY.

Rithm Capital Corporation

Rithm Capital is trending as investors debate whether the company's aggressive acquisition strategy and diversification into alternative asset management create a compelling undervaluation opportunity or excessive risk, particularly as the market navigates the potential impact of interest rate shifts on its mortgage servicing rights and REIT status. The community is actively discussing the stock's persistent discount to book value, speculating on future restructuring or spin-off possibilities, and weighing long-term growth potential against concerns over dilution and capital allocation.

Energous Corp. engages in the development of wireless charging technology. It focuses on the product, WattUp, a wireless power technology consisting of proprietary semiconductor chipsets, software controls, hardware designs, and antennas, that enables radio frequency based charging for electronic devices. The company was founded by Michael Aaron Leabman in 2012 and is headquartered in San Jose, CA.

Energous Corp

Energous Corp is gaining momentum as it transitions from development to commercial-scale deployments, with significant recent community attention driven by strong year-over-year revenue growth and expanded infrastructure in retail and logistics. Investors are closely monitoring the company's progress within the Ambient IoT ecosystem, particularly the integration with Amazon Web Services and successful rollout of PowerBridge units to major enterprise clients.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>While the fianlimab arm showed a numerical improvement in progression-free survival, the difference was not statistically significant, Regeneron said.</li><li>The company is continuing a separate late-stage trial comparing the same combination against Bristol Myers Squibb’s Opdualag.</li><li>The setback is a disappointment for Regeneron as it tries to carve out a position in the fast-growing melanoma immunotherapy market.</li></ul>Regeneron Pharmaceuticals (REGN) shares slipped marginally in after-hours trading on Friday after the company reported that its experimental drug fianlimab, combined with its approved medicine Libtayo, failed to meet the main goal of a pivotal late-stage melanoma trial.The late-stage study tested the combination against Merck’s blockbuster drug Keytruda in patients with advanced melanoma. While the fianlimab arm showed a numerical improvement in progression-free survival, the difference was not statistically significant, Regeneron said.In the high-dose arm, patients lived a median of 11.5 months without their cancer worsening, compared with 6.4 months for those on Keytruda alone. The lower-dose arm also fell short of statistical significance. No new safety concerns were reported, the company said.Regeneron said full results will be presented at a future medical meeting. The company is continuing a separate late-stage trial comparing the same combination against Bristol Myers Squibb’s Opdualag.The setback is a disappointment for Regeneron as it tries to carve out a position in the fast-growing melanoma immunotherapy market. Fianlimab plus Libtayo remains an investigational therapy with no approved indication yet.According to data from Koyfin, 22 of the 29 analysts covering REGN stock rate it ‘Buy’ or ‘higher’ while seven rate it ‘Hold’. The average 12-month price target on the stock is $875.31, representing a potential upside of about 25% from the last close.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around REGN stock stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.A Stocktwits user opined that REGN is in a “short-term downtrend.”<stembedurl>https://www.stocktwits.com/JetSetRepeat/message/653557494</stembedurl><a href="https://stocktwits.com/symbol/REGN">REGN stock</a> has gained 19% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/cadl-stock-edges-up-after-hours-on-strong-extended-prostate-cancer-data/cZXVNHpRekL">CADL Stock Edges Up After Hours On Strong Extended Prostate Cancer Data</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Regeneron Pharmaceuticals company logo is displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Regeneron’s Drug Combo Fails To Prove Superiority Over Merck’s Keytruda In Melanoma

The company tested its experimental drug fianlimab, combined with its approved medicine Libtayo, against Merck’s Keytruda in the trial. 

Equity

Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know  

Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.

Will Keytruda Continue to Aid MRK's Growth in 2026 After a Strong Q1?

Keytruda aids Merck's Q1 performance with $8B in sales. New indications plus combo therapies could fuel the drug's overall growth through 2026.

Moderna's Revenues See Strong International Momentum in Q1 Earnings

MRNA's Q1 revenues soar 260% on strong international vaccine sales, while cost cuts and new EU approvals support its broader growth strategy.

Merck Highlights New Long-Term Data and Advancements Across Broad Oncology Portfolio and Pipeline Research at ASCO 2026

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new research from more than 100 abstracts across over 25 types of cancer from the companys comprehensive oncology portfolio and pipeline will be presented at the 2026 American Society of Clinical Oncology...

The Zacks Analyst Blog  UnitedHealth, Merck & Co., Qualcomm, EVI and Optex 

UNH, MRK and QCOM drew focus as analysts highlighted growth drivers, pipeline strength and expanding AI and automotive opportunities.

Top Research Reports for UnitedHealth, Merck & Qualcomm

UnitedHealth, Merck and QUALCOMM lead Zacks' top research picks as analysts highlight growth drivers, earnings trends and key risks.

Merck Stock Down 7% in a Month: Should Investors Hold or Exit?

Merck falls 7% despite an earnings beat as a pipeline setback and Gardasil weakness act as dampeners. However, Keytruda and new launches support growth.

Merck Scientists Publish Landmark Paper on Novel Method for Large-Scale Biocatalytic Synthesis of Investigational Oral PCSK9 Inhibitor, Enlicitide Decanoate

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today the publication of work describing the large-scale synthesis of enlicitide decanoate, the companys...

Darzalex, Erleada & New Drugs Keep J&J's Oncology Engine Charged in Q1

Darzalex and new launches fuel J&J's 17.8% oncology sales growth in Q1 as the company targets $50B in cancer sales by 2030.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	$2.11	--	--	N/A
Q1 '26	-$1.47	-$1.28	13.15%	BEAT
Q4 '25	$2.01	$2.04	1.43%	BEAT
Q3 '25	$2.35	$2.58	9.90%	BEAT
Q2 '25	$2.02	$2.13	5.40%	BEAT

MRK
Merck & Co Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q1 '26

Historical Earnings

Latest MRK News

MRKMerck & Co Inc